Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sotio Biotech Inc.
M.D. Anderson Cancer Center
Kaiser Permanente
Institut du Cancer de Montpellier - Val d'Aurelle
Jonsson Comprehensive Cancer Center
University of Colorado, Denver
RenJi Hospital
Degron Therapeutics Co.
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.
Columbia University
Theratechnologies
SOLTI Breast Cancer Research Group
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Universidade Federal de Pernambuco
Salubris Biotherapeutics Inc
TransThera Sciences (Nanjing), Inc.
M.D. Anderson Cancer Center
University Medical Center Groningen
Hoffmann-La Roche
Kineta Inc.
Institut Bergonié
Blue Note Therapeutics
MacroGenics
Lumos Pharma
Celgene
Zhujiang Hospital
Pfizer
Amgen
National Cancer Institute (NCI)